相关实验视频

Updated: Jul 12, 2025

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

针对COVID-19的Aptamers的临床翻译

Yang Zhang¹, Yongen Li¹

¹College of Science, Harbin Institute of Technology (Shenzhen), Shenzhen, Guangdong 518055, China.

Journal of medicinal chemistry

|October 25, 2023

概括

适应剂显示出用于诊断和治疗COVID-19的前景,包括变种和长期COVID. 然而,临床翻译是缓慢的,克服这些挑战对于推进aptamer技术至关重要.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
传染性疾病传染性疾病

背景情况:

严重急性呼吸系统综合征-冠状病毒-2 (SARS-CoV-2) 仍然是一个重大的全球健康威胁,导致广泛的死亡率.
虽然存在COVID-19的诊断和治疗策略,但需要新的方法来对抗新出现的SARS-CoV-2变种,并解决长期COVID的复杂性.
基于核酸的分子类型的aptamers已经成为开发针对SARS-CoV-2的先进诊断和治疗工具的有希望的候选人.

研究的目的:

突出APTAMER在解决COVID-19管理中未满足的需求方面的潜力.
讨论阻碍基于aptamer的技术临床转化所面临的挑战.
强调克服这些障碍对于未来在传染病中的应用的重要性.

主要方法:

对SARS-CoV-2的aptamer开发现有文献的审查.
分析与阿普他默稳定性,输送和临床验证相关的挑战.
探索潜在的策略,以提高阿普他默的疗效,并促进临床采用.

主要成果:

阿普塔默对SARS-CoV-2点具有很高的特异性和亲和力,显示出敏感诊断的潜力.
胺酶的治疗应用包括病毒中和和对宿主反应的调制.
临床转换的重大障碍包括免疫性,核酶降解和经济高效的大规模生产.

结论:

阿普塔默是一种具有实质潜力的多功能平台,可以对抗SARS-CoV-2,其变种和长期COVID.
解决目前在aptamer开发和临床实施方面的局限性对于实现其全部治疗和诊断能力至关重要.
进步的aptamer技术不仅将使COVID-19患者的护理受益,还将为治疗其他关键疾病铺平道路.

更多相关视频

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

相关概念视频

Leaky Scanning

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...

Initiation of Translation

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...